ERBB2 and non-small cell lung carcinoma: Until now, no major oncology guidelines recommend using T-DXd in the neoadjuvant or adjuvant settings for HER2-mutant NSCLC (CSCO, 2024; NCCN, 2024), and its perioperative use remains investigational.